Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LQDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LQDA
Wall Street analysts forecast LQDA stock price to fall
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.030
Low
31.00
Averages
47.50
High
67.00
Current: 62.030
Low
31.00
Averages
47.50
High
67.00
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Liquidia CEO Sells 75,000 Shares
- Executive Sell-off: Liquidia's CEO Roger Jeffs sold 75,000 shares on May 21, 2026, which may raise concerns about the company's future prospects, as executive sell-offs are often perceived as a lack of confidence in the company.
- Market Reaction: This sell-off could lead to a decline in investor confidence in Liquidia's stock, potentially impacting its price performance, especially in the current market environment where investors are highly sensitive to executive actions.
- Shareholding Structure Change: Jeffs' sell-off may alter Liquidia's shareholder structure, affecting corporate governance and decision-making processes, particularly if executive ownership is significant, which could prompt a reevaluation of the company's strategic direction.
- Uncertain Future Outlook: This sell-off may create doubts about Liquidia's future development, especially as the company has not released its latest financial data, leading investors to question its profitability and growth potential.
See More
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Caprock Group Reduces Liquidia Stake in Q1
- Share Reduction Transaction: Caprock Group sold 416,686 shares of Liquidia in Q1 2026, with an estimated transaction value of $15.46 million, indicating a strategic adjustment in its holding approach towards Liquidia.
- Position Change: After the sale, Caprock's Liquidia holdings decreased to 1,367,235 shares valued at $51.60 million, with a net position change reflecting a decrease of $9.93 million, suggesting a focus on managing investment risk.
- Performance Highlights: Liquidia generated approximately $130 million in YUTREPIA sales during Q1, achieving a net income of $53 million, demonstrating an accelerating commercialization process and marking its third consecutive profitable quarter.
- Market Performance: Liquidia's stock price surged nearly 260% over the past year, significantly outperforming the S&P 500's 26% gain, reflecting strong market demand for its innovative therapies and potential for future growth.
See More
Liquidia Corp Reports Strong Q1 Earnings Exceeding Expectations
- Strong Performance: Liquidia Corp reported Q1 earnings of $0.52 per share, exceeding market expectations, which demonstrates the company's robust performance in the biopharmaceutical sector and is likely to boost investor confidence.
- Sales Growth: The company achieved sales of $132.865 million, significantly increasing compared to the same period last year, reflecting the competitiveness and sustained demand for its products, which may drive future revenue growth.
- Analyst Optimism: Several analysts have raised their price targets for Liquidia Corp stock, indicating an increased market confidence in its future performance, which could attract more investor interest in the stock.
- Positive Market Reaction: Due to the better-than-expected results and analysts' optimistic outlook, Liquidia Corp's stock is likely to experience a positive market reaction in the short term, further driving up its share price.
See More
Liquidia (LQDA) Q1 2026 Earnings Transcript
See More
JW Asset Management Sells Liquidia Shares
- Share Reduction Transaction: On May 8, 2026, JW Asset Management sold 83,600 shares of Liquidia Corporation, with an estimated transaction value of $3.10 million, reducing its stake to 0.25% of its total U.S. equity assets.
- Value Change in Holdings: Following the sale, JW Asset Management's holdings in Liquidia decreased to 16,176 shares worth $610,482, with a net position value decline of $2.83 million during the period, indicating a potential loss of confidence in the company.
- Strong Market Performance: As of May 7, 2026, Liquidia shares were priced at $42.28, reflecting a 175% increase over the past year, significantly outperforming the S&P 500 by approximately 145 percentage points, showcasing its robust position in the biopharmaceutical market.
- Sales Growth of Products: Liquidia's inhaled drug YUTREPIA generated $148.3 million in net product sales in 2025, including $90.1 million in the fourth quarter alone, indicating strong market demand in the pulmonary arterial hypertension treatment sector.
See More
Liquidia CEO Sells 75,000 Shares
- Executive Sell-off: Liquidia's CEO Roger Jeffs sold 75,000 shares on May 21, 2026, which may raise concerns about the company's future prospects, as executive sell-offs are often perceived as a lack of confidence in the company.
- Market Reaction: This sell-off could lead to a decline in investor confidence in Liquidia's stock, potentially impacting its price performance, especially in the current market environment where investors are highly sensitive to executive actions.
- Shareholding Structure Change: Jeffs' sell-off may alter Liquidia's shareholder structure, affecting corporate governance and decision-making processes, particularly if executive ownership is significant, which could prompt a reevaluation of the company's strategic direction.
- Uncertain Future Outlook: This sell-off may create doubts about Liquidia's future development, especially as the company has not released its latest financial data, leading investors to question its profitability and growth potential.
See More
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Caprock Group Reduces Liquidia Stake in Q1
- Share Reduction Transaction: Caprock Group sold 416,686 shares of Liquidia in Q1 2026, with an estimated transaction value of $15.46 million, indicating a strategic adjustment in its holding approach towards Liquidia.
- Position Change: After the sale, Caprock's Liquidia holdings decreased to 1,367,235 shares valued at $51.60 million, with a net position change reflecting a decrease of $9.93 million, suggesting a focus on managing investment risk.
- Performance Highlights: Liquidia generated approximately $130 million in YUTREPIA sales during Q1, achieving a net income of $53 million, demonstrating an accelerating commercialization process and marking its third consecutive profitable quarter.
- Market Performance: Liquidia's stock price surged nearly 260% over the past year, significantly outperforming the S&P 500's 26% gain, reflecting strong market demand for its innovative therapies and potential for future growth.
See More
Liquidia Corp Reports Strong Q1 Earnings Exceeding Expectations
- Strong Performance: Liquidia Corp reported Q1 earnings of $0.52 per share, exceeding market expectations, which demonstrates the company's robust performance in the biopharmaceutical sector and is likely to boost investor confidence.
- Sales Growth: The company achieved sales of $132.865 million, significantly increasing compared to the same period last year, reflecting the competitiveness and sustained demand for its products, which may drive future revenue growth.
- Analyst Optimism: Several analysts have raised their price targets for Liquidia Corp stock, indicating an increased market confidence in its future performance, which could attract more investor interest in the stock.
- Positive Market Reaction: Due to the better-than-expected results and analysts' optimistic outlook, Liquidia Corp's stock is likely to experience a positive market reaction in the short term, further driving up its share price.
See More
Liquidia (LQDA) Q1 2026 Earnings Transcript
See More
JW Asset Management Sells Liquidia Shares
- Share Reduction Transaction: On May 8, 2026, JW Asset Management sold 83,600 shares of Liquidia Corporation, with an estimated transaction value of $3.10 million, reducing its stake to 0.25% of its total U.S. equity assets.
- Value Change in Holdings: Following the sale, JW Asset Management's holdings in Liquidia decreased to 16,176 shares worth $610,482, with a net position value decline of $2.83 million during the period, indicating a potential loss of confidence in the company.
- Strong Market Performance: As of May 7, 2026, Liquidia shares were priced at $42.28, reflecting a 175% increase over the past year, significantly outperforming the S&P 500 by approximately 145 percentage points, showcasing its robust position in the biopharmaceutical market.
- Sales Growth of Products: Liquidia's inhaled drug YUTREPIA generated $148.3 million in net product sales in 2025, including $90.1 million in the fourth quarter alone, indicating strong market demand in the pulmonary arterial hypertension treatment sector.
See More
